WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997013514) NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/013514    International Application No.:    PCT/IB1996/001042
Publication Date: 17.04.1997 International Filing Date: 02.10.1996
Chapter 2 Demand Filed:    12.03.1997    
IPC:
A61K 31/439 (2006.01), A61K 31/451 (2006.01), A61K 31/454 (2006.01), A61K 31/4709 (2006.01)
Applicants: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017-5755 (US) (For All Designated States Except US).
PIEDIMONTE, Giovanni [IT/US]; (US).
HESS, Hans, J. [US/US]; (US) (For US Only).
LOWE, John, A., III [US/US]; (US) (For US Only)
Inventors: PIEDIMONTE, Giovanni; (US).
HESS, Hans, J.; (US).
LOWE, John, A., III; (US)
Agent: RICHARDS, John; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US)
Priority Data:
60/005,002 10.10.1995 US
60/006,344 07.11.1995 US
Title (EN) NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY
(FR) ANTAGONISTES DU RECEPTEUR NK1 SERVANT A PREVENIR L'INFLAMMATION NEUROGENE EN THERAPIE GENIQUE
Abstract: front page image
(EN)The present invention relates to a method of preventing or treating the neurogenic inflammation associated with the use of viral vectors in gene therapy in a mammal, including a human, by administering to the mammal an NK-1 receptor antagonist (e.g., a substance P receptor antagonist).
(FR)L'invention concerne un procédé de prévention ou de traitement de l'inflammation neurogène associée à l'utilisation de vecteurs viraux en thérapie génique chez un mammifère, y compris l'homme, par administration audit mammifère d'un antagoniste du récepteur NK1 (par exemple, un antagoniste du récepteur de la substance P).
Designated States: CA, JP, MX, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)